A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection

AIDS

Volumn 12, Issue 8, 1998, Pages

  Rutschmann, Olivier T ^a   Opravil, Milos ^b   Iten, Anne ^c   Malinverni, Raffaele ^d   Vernazza, Pietro L ^e   Bucher, Heiner C ^f   Bernasconi, Enos ^g   Sudre, Philippe ^a   Leduc, Dominique ^a   Yerly, Sabine ^a   Perrin, Luc H ^a   Hirschel, Bernard ^a,h  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d PSI   (Switzerland)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g Ospedale Civico Lugano   (Switzerland)

^h Faculty of Medicine   (Switzerland)

Author keywords

Antiretroviral therapy; Didanosine; Hydroxyurea; Stavudine

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; HYDROXYUREA; STAVUDINE; VIRUS RNA;

ABDOMINAL PAIN; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DISEASE MARKER; DOUBLE BLIND PROCEDURE; FATIGUE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; NAUSEA; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; SWITZERLAND; VIREMIA; VOMITING;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DIDANOSINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; HYDROXYUREA; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, VIRAL; STAVUDINE; SWITZERLAND; VIREMIA;

EID: 7144257857     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199808000-00003     Document Type: Article

References (33)

1. Hammer SM, Katzenstein DA, Hughes MD, et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996, 335:1081-1090.
2. Cooper DA, Katlama C, Montaner J, et al.: Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial. Lancet 1997, 349:1413-1421.
3. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
4. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
5. Merrill DP, Moonis M, Chou TC, Hirsch MS: Lamivudine or stavudine in two-and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J Infect Dis 1996, 173:355-364.
6. Kline MW, Fletcher CV, Federici ME, et al.: Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologie and virologie effects. Pediatrics 1996, 97:886-890.
7. Lori F, Malykh A, Cara A, et al.: Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994, 266:801-805.
8. Gao WY, Johns DG, Chokekuchai S, Mitsuya H: Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2′,3′-dideoxynucleoside activities against replication of human immunodeficiency virus. Proc Natl Acad Sci USA 1995, 92:8333-8337.
9. Malley SD, Grange JM, Hamedi Sangsari F, Vila JR: Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compound with 2′,3′-dideoxyinosine in infected resting human lymphocytes. Proc Natl Acad Sci USA 1994, 91:11017-11021.
10. Biron F, Lucht F, Peyramond D, et al.: Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 10:36-40.
11. Montaner JSG, Zala C, Conway B, et al.: A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV Trials Network Protocol 088. J Infect Dis 1997, 175:801-806.
12. Vila J, Nugier F, Barguès G, et al.: Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide. Lancet 1997, 348:203-204.
13. Anon: Treatment issues' second survey of physicians' treatment practice. GMHC 1998, 12:3-17.
14. Ledergerber B, von Overbeck J, Egger M, Lüthy R, Swiss HIV Cohort Study: The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. Soz Präventivmed 1994, 39:387-394.
15. Sous-Commission 'Clinique' de la Commission Fédérale sur les Questions Liées au SIDA: Directives pour l'utilisation des médicaments antiviraux dans le traitement de l'infection par le VIH. Bull Office Féd Samé Publique 1996, 29:5-7.
16. Schockmel GA, Yerly S, Perrin L: Detection of low HIV-1 RNA levels in plasma. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 14:179-183.
17. Katzenstein DA, Hammer SM, Hughes MD, et al.: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996, 335:1091-1098.
18. Egger M: Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective muticentre study. BMJ 1997, 315:1194-1199.
19. Hughes MD, Johnson VA, Hirsch MS, et al.: Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med 1997, 126:929-938.
20. O'Brien WA, Hartigan PM, Martin D, et al.: Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996, 334:426-431.
21. Lafeuillade A, Pellegrino P, Poggi C, Profizi N, Thiehaut C: Hydroxyurea and HIV-1 viraemia [letter]. AIDS 1995, 9:1290-1291.
22. Gazzard BG, Moyle GJ, Weber J, et al.: British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997, 349:1086-1092.
23. Eron JJ, Benoit SL, Jemsek J, et al.: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995, 333:1662-1669.
24. Foli A, Lori F, Maserati R, Tinelli C, Minoli L, Lisziewirz J: Hydroxyurea and didanosine is a more potent combination thant hydroxyurea and zidovudine. Antiviral Ther 1997, 2:31-40.
25. Portegies P: HIV-1, the brain, and combination therapy. Lancet 1995, 346:1244-1245.
26. Schuurman R, Nijhuis M, Van Leeuwen R, et al.: Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995, 171:1411-1419.
27. 3:AIDS Clinical Trials Group protocol 208. J Infect Dis 1995, 172:1379-1383.
28. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
29. Winters MA, Schapiro JM, Lawrence J, Merigan TC: Genotypic and phenotypic analysis of the protease gene in HIV-1-infected patients that failed long-term saquinavir therapy and switched to other protease inhibitors [abstract]. Antiviral Ther 1997, 11:17.
30. Lin P-F, Samanta H, Rose RE, et al.: Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis 1994, 170:1157-1164.
31. Kozal MJ, Kroodsma K, Winters MA, et al.: Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Ann Intern Med 1994, 121:263-268.
32. De Antoni A, Foli A, Lisziewicz J, Lori F: Mutations in the pol gene of HIV-1 in infected patients receiving didanosine and hydroxyurea combination therapy. J Infect Dis 1997, 176:899-903.
33. Lori F, Malykh AG, Foli A, et al.: Combination of a drug targeting the cell with a drug targeting the virus controls HIV-1 resistance. AIDS Res Hum Retroviruses 1997, 13:1403-1409.